

Thomas Pieber

Head of Clinical Trials Program

Division of Endocrinology and Diabetology, Department of Internal Medicine
Medical University of Graz

ORCID ID: <https://orcid.org/0000-0003-3554-0405>

SCIENTIFIC & ACADEMIC CAREER

Since 2008	Full Professor of Medicine, Chair Division of Endocrinology and Diabetology at Medical University of Graz
Since 2001	Director, HEALTH - Institute for – Institute for Biomedical Research and Technologies at JOANNEUM RESEARCH
Since 2015	Founder and Chief Scientific Officer (CSO), CBmed - Center for Biomarker
1997	Associate Professor of Medicine
2000	Board Certification of Intensive Care Medicine, Austria
1997	Board Certification of Endocrinology and Metabolism, Austria
1993	Board Certification of Internal Medicine, Austria
1987 – 1993	Fellowship in Internal Medicine at Heinrich-Heine-University Düsseldorf, Germany; Southwestern Medical Center Dallas, University of Texas, USA; University Hospital Graz, Austria
1980 – 1987	Karl-Franzens-University School of Medicine, Graz, Austria, (MD 1987)

MAIN AREA OF RESEARCH

Thomas Pieber and his group have developed and tested several new therapeutic concepts for the type 1 and type 2 diabetes, from new pharmacological interventions to innovative medical devices. In the recent years his research focus expanded to biomarker research in oncology and cardiovascular disease, to strategies for disease prevention and healthy aging. Thomas Pieber was and currently is lead principal investigator (PI) in several international study groups and multicenter trials funded by the EU Commission and foundations such as JDRF and LRA in the USA. In INNODIA, a project funded by the EU Commission, Dr. Pieber is lead PI of the largest investigator-initiated study, the Ver-A-T1D trial, which investigates mechanisms of β -cell protection in type 1 diabetes. In the field of aging and age-related diseases he has translated results from basic research into innovative and groundbreaking clinical trials. He also founded and built up CBmed, a public funded research center in the field of biomarker research.

ADDITIONAL RESEARCH ACTIVITIES (*10 most important*)

Since 1988	Co-Founder and permanent member of David-Herzog-Fund of the Styrian Universities (www.dhf.org)
Since 1998	Member of International Working Group of the Diabetic Foot
1999 – 2007	Member of the Postgraduate Educational Subcommittee of the European Association for the Study of Diabetes (EASD)
Since 2015	Member of the Management Team and Principal Investigator in the EU-funded IMI2 consortia INNODIA and INNODIA-Harvest
Since 2018	Investigator in the EU-funded IMI2 consortium Hypo-RESOLVE
Since 2020	Principal Investigator of the BioTechMed-funded consortium MIDAS
Since 2021	Principal Investigator of the JDRF- and SLE-funded consortium COMET

Selected Presentations

09 / 2018	“EASE Programme: Empagliflozin as an adjunct to insulin in type 1 diabetes. Independent Commentary” Annual Meeting of the EASD, Berlin, Germany
10 / 2018	“Diabetes management update: Focus on cardiovascular disease prevention” World Conference in Internal Medicine, Cape Town, South Africa
04 / 2019	“Artificial pancreas in type 1 diabetes – will we ever get there?” Endocrine Grand Rounds, Visiting Professor at the University of Arizona, Tucson, USA
06 / 2019	“Hypoglycemia and Cardiovascular Events – A Casual Relationship” Annual Meeting of the American Diabetes Association (ADA), San Francisco, USA
12 / 2019	“Prevention of Type 1 Diabetes” World Congress of the International Diabetes Federation (IDF), Busan, South Korea
06 / 2020	„Which Diet Is Best for Treatment of Diabetes and Obesity? Intermittent Fasting” Annual Meeting of the American Diabetes Ass., USA
09 / 2021	“The future of incretin based treatments: Established items in new packaging” Annual Meeting of the EASD

Honors & Awards

1990 - 1992	Research Fellowship (Max-Kade-Scholarship), Austrian Academy of Sciences
2000	Research Award of the University Graz
2003	eEurope Awards for "ehealth - 2003" of the EU-Commission
2004	Research Award of the Medical University Graz
2005	University Award of “Industriellenvereinigung Steiermark”
2010	Somogyi Award
2011	Fast Forward Award of the Styrian Government
2014	Research Award Human Technology Interface, Styria
1997, 1999, 2019	Stefan Schuy Award of the Austrian Biomedical Society
2021	EFSD and Novo Nordisk Foundation Diabetes Precision Medicine Award

10 MOST IMPORTANT PUBLICATIONS

1. Svehlikova, E; Ashcroft, NL; Gatschelhofer, C; Gerring, D; Holler, V; Jezek, J; Lackner, B; Lawrence, F; Pillai, V; Ratzer, M; Urschitz, M; Wolf, M; **Pieber, TR**, (2023) Pharmacokinetics and Pharmacodynamics of a Novel U500 Insulin Aspart Formulation: A Randomized, Double-Blind, Crossover Study in People With Type 1 Diabetes. *Diabetes Care* 2023; 46(4): 757-764 [Doi: 10.2337/dc22-1054](https://doi.org/10.2337/dc22-1054)
2. Svehlikova, E; Mursic, I; Augustin, T; Magnes, C; Gerring, D; Jezek, J; Schwarzenbacher, D; Ratzer, M; Wolf, M; Howell, S; Zakrzewski, L; Urschitz, M; Tschapeller, B; Gatschelhofer, C; Feichtner, F; Lawrence, F; **Pieber, TR** (2021). Pharmacokinetics and Pharmacodynamics of Three Different Formulations of Insulin Aspart: A Randomized, Double-Blind, Crossover Study in Men With Type 1 Diabetes. *Diabetes Care*; 44(2): 448-455 [Doi: 10.2337/dc20-1017](https://doi.org/10.2337/dc20-1017)
3. von Herrath, M; Bain, SC; Bode, B; Clausen, JO; Coppieters, K; Gaysina, L; Gumprecht, J; Hansen, TK; Mathieu, C; Morales, C; Mosenzon, O; Segel, S; Tsoukas, G; **Pieber, TR** (2021); Anti-IL-21–liraglutide Study Group investigators and contributors. Anti-interleukin-21 antibody and liraglutide for the preservation of β -cell function in adults with recent-onset type 1 diabetes: a randomised, double-blind, placebo-controlled, phase 2 trial. *Lancet Diabetes Endocrinol*; 9: 212–224 [Doi: 10.1016/S2213-8587\(21\)00019-X](https://doi.org/10.1016/S2213-8587(21)00019-X)
4. Stekovic, S; Hofer, SJ; Tripolt, N; Aon, MA; Royer, P; Pein, L; Stadler, JT; Pendl, T; Prietl, B; Url, J; Schroeder, S; Tadic, J; Eisenberg, T; Magnes, C; Stumpe, M; Zuegner, E; Bordag, N; Riedl, R; Schmidt, A; Kolesnik, E; Verheyen, N; Springer, A; Madl, T; Sinner, F; de Cabo, R; Kroemer, G; Obermayer-Pietsch, B; Dengjel, J; Sourij, H; **Pieber, TR**; Madeo, F (2019). Alternate Day Fasting Improves Physiological and Molecular Markers of Aging in Healthy, Non-obese Humans. *Cell Metab.* 2019;30: 462-476 [Doi: 10.1016/j.cmet.2019.07.016](https://doi.org/10.1016/j.cmet.2019.07.016)
5. **Pieber, TR**; Bode, B; Mertens, A; Cho, YM; Christiansen, E; Hertz, CL; Wallenstein, SOR; Buse, JB; PIONEER 7 investigators (2019). Efficacy and safety of oral semaglutide with flexible dose adjustment versus sitagliptin in type 2 diabetes (PIONEER 7): a multicentre, open-label, randomised, phase 3a trial. *Lancet Diabetes Endocrinol*; 7(7): 528-539 [Doi: 10.1016/S2213-8587\(19\)30194-9](https://doi.org/10.1016/S2213-8587(19)30194-9)
6. Davies, M; **Pieber, TR**; Hartoft-Nielsen, ML; Hansen, OKH; Jabbour, S; Rosenstock, J (2017). Effect of Oral Semaglutide Compared With Placebo and Subcutaneous Semaglutide on Glycemic Control in Patients With Type 2 Diabetes: A Randomized Clinical Trial. *JAMA*; 318(15): 1460-1470 [Doi: 10.1001/jama.2017.14752](https://doi.org/10.1001/jama.2017.14752)
7. Marso, SP; McGuire, DK; Zinman, B; Poulter, NR; Emerson, SS; **Pieber, TR**; Pratley, RE; Haahr, PM; Lange, M; Brown-Frandsen, K; Moses, A; Skibsted, S; Kvist, K; Buse, JB; DEVOTE Study Group (2017). Efficacy and Safety of Degludec versus Glargine in Type 2 Diabetes. *N Engl J Med*; 377(8): 723-732 [Doi: 10.1056/NEJMoa1615692](https://doi.org/10.1056/NEJMoa1615692)
8. Eisenberg, T; Abdellatif, M; Schroeder, S; Primessnig, U; Stekovic, S; Pendl, T; Harger, A; Schipke, J; Zimmermann, A; Schmidt, A; Tong, M; Ruckstuhl, C; Dammbroeck, C; Gross, AS; Herbst, V; Magnes, C; Trausinger, G; Narath, S; Meinitzer, A; Hu, Z; Kirsch, A; Eller, K; Carmona-Gutierrez, D; Büttner, S; Pietrocola, F; Knittelfelder, O; Schrepfer, E; Rockenfeller, P; Simonini, C; Rahn, A; Horsch, M; Moreth, K; Beckers, J; Fuchs, H; Gailus-Durner, V; Neff, F; Janik, D; Rathkolb, B; Rozman, J; de Angelis, MH; Moustafa, T; Haemmerle, G; Mayr, M; Willeit, P; von Frieling-Salewsky, M; Pieske, B; Scorrano, L; **Pieber, TR**; Pechlaner, R; Willeit, J; Sigrist, SJ; Linke, WA; Mühlfelder, C; Sadoshima, J; Dengjel, J; Kiechl, S; Kroemer, G; Sedej, S; Madeo, F (2016). Cardioprotection and lifespan extension by the natural polyamine spermidine. *Nat Med*; 22(12): 1428-1438 [Doi: 10.1038/nm.4222](https://doi.org/10.1038/nm.4222)

9. Thabit, H; Tauschmann, M; Allen, JM; Leelarathna, L; Hartnell, S; Wilinska, ME; Acerini, CL; Dellweg, S; Benesch, C; Heinemann, L; Mader, JK; Holzer, M; Kojzar, H; Exall, J; Yong, J; Pichierri, J; Barnard, KD; Kollman, C; Cheng, P; Hindmarsh, PC; Campbell, FM; Arnolds, S; **Pieber, TR**; Evans, ML; Dunger, DB; Hovorka, R; APCam Consortium and AP@home Consortium (2015). Home Use of an Artificial Beta Cell in Type 1 Diabetes. *N Engl J Med.*; 373(22): 2129-2140 Doi: [10.1056/NEJMoa1509351](https://doi.org/10.1056/NEJMoa1509351)
10. Eisenberg, T; Schroeder, S; Andryushkova, A; Pendl, T; Küttner, V; Bhukel, A; Mariño, G; Pietrocola, F; Harger, A; Zimmermann, A; Moustafa, T; Sprenger, A; Jany, E; Büttner, S; Carmona-Gutierrez, D; Ruckenstein, C; Ring, J; Reichelt, W; Schimmel, K; Leeb, T; Moser, C; Schatz, S; Kamolz, LP; Magnes, C; Sinner, F; Sedej, S; Fröhlich, KU; Juhasz, G; **Pieber, TR**; Dengjel, J; Sgrist, SJ; Kroemer, G; Madeo, F (2014). Nucleocytosolic depletion of the energy metabolite acetyl-coenzyme a stimulates autophagy and prolongs lifespan. *Cell Metab*; 19(3): 431-444 Doi: [10.1016/j.cmet.2014.02.010](https://doi.org/10.1016/j.cmet.2014.02.010)